Bassily S, Hyams K C, el-Ghorab N M, Mansour M M, el-Masry N A, Dunn M A
Am J Trop Med Hyg. 1987 May;36(3):549-53. doi: 10.4269/ajtmh.1987.36.549.
Because dual infection with Schistosoma mansoni and hepatitis B may lead to severe liver disease, populations living in schistosomiasis-endemic areas might benefit if effectively immunized against hepatitis B. To determine whether a plasma-derived hepatitis B vaccine is immunogenic in patients with schistosomiasis, 32 individuals infected with S. mansoni were given three 20-micrograms doses of Heptavax-B vaccine and treated with praziquantel. Antibody to hepatitis B surface antigen developed in 90.6% of the study subjects after three doses of vaccine. Five patients (15.6%) had a weak response to the vaccine, and three patients (9.4%) failed to develop antibody. A weak or failed response to the vaccine was significantly associated with the presence of hepatosplenomegaly. A plasma-derived vaccine is immunogenic for persons infected with S. mansoni; however, vaccine response is diminished in hepatosplenic schistosomiasis.
由于曼氏血吸虫和乙型肝炎的双重感染可能导致严重的肝脏疾病，生活在血吸虫病流行地区的人群若能有效接种乙型肝炎疫苗可能会受益。为了确定血浆源性乙型肝炎疫苗对血吸虫病患者是否具有免疫原性，对32名感染曼氏血吸虫的个体给予三剂20微克的Heptavax-B疫苗，并进行吡喹酮治疗。三剂疫苗接种后，90.6%的研究对象产生了乙型肝炎表面抗原抗体。5名患者（15.6%）对疫苗反应较弱，3名患者（9.4%）未产生抗体。对疫苗反应较弱或无反应与肝脾肿大显著相关。血浆源性疫苗对感染曼氏血吸虫的人具有免疫原性；然而，在肝脾型血吸虫病中疫苗反应会减弱。
